update: Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Makers of Psoriasis
December 23, 2014 at 06:02 AM EST
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com), a development-stage oncology and dermatology biopharmaceutical ...